Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

Sponsor
Bristol-Myers Squibb
Study ID
NCT06566768
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to identify drug levels of gastro-retentive (GR) formulations which prolong retaining time in the stomach of deucravacitinib (BMS-986165) in Healthy Participants.

Key Dates

First listed
Aug 22, 2024
Start date
Oct 7, 2024
Status verified
Jun 2025
Primary completion
Jun 13, 2025
Completion
Jun 13, 2025

Study Design

Enrollment
52 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: Deucravacitinib
  • Experimental: Part B: Deucravacitinib

Primary Outcome Measure

Maximum observed plasma concentration (Cmax) [ Time Frame: Up to approximately 5 days ]

Related Studies